Printer Friendly

Proton Partners International to Fight Cancer with Elekta Radiotherapy Equipment.

M2 PHARMA-November 30, 2015-Proton Partners International to Fight Cancer with Elekta Radiotherapy Equipment

(C)2015 M2 COMMUNICATIONS

- Swedish medical technology company Elekta (EKTA-B.ST) is to help Welsh proton beam therapy company Proton Partners International achieve its goal of creating hubs of excellence for advanced cancer treatment in the UK by providing the latest technology in radiotherapy, the company said on Monday.

Proton Partners International is to open centres in the UK.

In addition to proton therapy, the centres will offer radiotherapy and chemotherapy to treat, private patients under medical insurance and self-pay patients and NHS patients.

Proton Partners will acquire Elekta Versa HD systems, the most modern linear accelerator on the market, as well as Elekta MOSAIQ offering a fully integrated OIS consisting of MOSAIQ radiation oncology, MOSAIQ medical oncology and MOSAIQ proton therapy.

The Versa HD systems and MOSAIQ software will be installed at the centers in Newport, Wales and Northumberland, England. The order is valued at more than GBP 5 m and was booked during Elekta's second fiscal quarter.

According to Cancer Research UK, the number of new cancer cases each year in the UK is expected to reach around 432,000 by 2030, and half of these patients should receive radiotherapy at some point in their treatment.

The precision and speed of Versa HD, it's advanced beam-shaping, imaging and high dose rate technologies make it perfect for treating both conventional and complex cancer cases.

Elekta develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.

Currently, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally.

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Karol Sikora, former head of the World Health Organisation's cancer programme, Chris Evans, the life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost GBP 100m equity finance in the company.

Gordon McVie, senior consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed chairman and Karol Sikora is chief medical adviser to the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Nov 30, 2015
Words:388
Previous Article:Heptares signs strategic drug discovery collaboration with Pfizer across multiple therapeutic areas.
Next Article:Expansion of US Medicaid Programme Offers Breast Cancer Screening Improvements for Low-Income Women.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters